Skip to main content
NCBI home page
Springer logoLink to Springer
. 2023 Apr 8;30(4):519–530. doi: 10.1007/s12282-023-01455-4

Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition

Tsunehisa Nomura 1,✉, Masaaki Kawai 2, Yuna Fukuma 1, Yoshikazu Koike 1, Shinji Ozaki 3, Motoki Iwasaki 4, Seiichiro Yamamoto 5, Kiyoshi Takamatsu 6, Hitoshi Okamura 7, Masami Arai 8, Shoichiro Ootani 9, Hiroji Iwata 10, Shigehira Saji 11
PMCID: PMC10284729  PMID: 37029889

Abstract

Alcohol consumption is internationally recognized as one of the compelling risk factors for breast cancer, but it does not necessarily correlate with the prognosis of breast cancer patients. Alcohol consumption in breast cancer patients was addressed in the 2022 Breast Cancer Clinical Practice Guidelines. A systematic review and meta-analysis of epidemiological studies on alcohol consumption and breast cancer recurrence, breast cancer-related mortality, all-cause mortality, and cardiovascular disease mortality in breast cancer patients was performed. The PubMed, Cochrane Library, and Ichushi-Web databases were searched for relevant publications reporting cohort or case–control studies published until March 2021. A total of 33 studies (32 cohort studies and 1 case–control study) met the eligibility criteria; 4638 cases of recurrence, 12,209 cases of breast cancer-specific mortality, and 21,945 cases of all-cause mortality were observed. With regard to breast cancer recurrence, 7 studies assessed pre-diagnosis alcohol consumption (relative risk (RR) 1.02, 95% confidence interval (95% CI) 0.77–1.37, p = 0.88) and 3 studies assessed post-diagnosis alcohol consumption (RR 0.96, 95% CI 0.85–1.10, p = 0.57), and no significant increase or decrease in risk was observed. With regard to breast cancer-related mortality, 19 studies assessed pre-diagnosis alcohol consumption (RR 1.02, 95% CI 0.93–1.11, p = 0.69), 9 studies assessed post-diagnosis alcohol consumption (RR 0.96, 95% CI 0.77–1.19, p = 0.70), and no significant increase or decrease in risk was observed. With regard to all-cause mortality, 18 studies assessed pre-diagnosis alcohol consumption (RR 0.90, 95% CI 0.82–0.99, p = 0.02), 8 studies assessed post-diagnosis alcohol consumption (RR 0.88, 95% CI 0.74–1.02, p = 0.08), and pre-diagnosis alcohol consumption was associated with a significantly decreased risk. With regard to cardiovascular disease mortality and alcohol consumption, 2 studies assessed it, and the RRwas 0.47 (95% CI 0.28–0.79, p = 0.005), showing that alcohol consumption was associated with a significantly decreased risk. The limitations of this study are that drinking status was mainly based on a questionnaire survey, which is somewhat inaccurate and has many confounding factors, and the cut-off value for the maximum alcohol intake in many studies was low, and it is possible that the actual intake was only an appropriate amount. In many countries, a standard drinking amount is set, and wise decisions are required.

Keywords: Alcohol consumption, Breast cancer, Systematic review, Meta-analysis

Introduction

Alcohol consumption is internationally recognized as one of the compelling risk factors for breast cancer. Ethanol contained in alcoholic beverages and its metabolite acetaldehyde have been experimentally shown to be carcinogenic [1]. However, the increased risk of breast cancer due to alcohol consumption does not necessarily correlate with the prognosis of breast cancer patients. Even in breast cancer patients, there are many occasions where alcoholic beverages are preferred in daily life or social gatherings. It is a modifiable factor through individual effort, and accurate information is required.

In June 2022, the Japanese Breast Cancer Society practice guidelines, the 2022 edition, was published by the Japanese Breast Cancer Society. In the guidelines, we addressed the clinical question, “Is alcohol consumption associated with prognosis in breast cancer patients?” To make recommendations for this clinical question, we assessed the benefits and harms of alcohol consumption after patients were diagnosed with breast cancer by performing a systematic review and meta-analysis of the relevant literature. The results of this systematic review and meta-analysis are reported.

Methods

A quantitative and qualitative systematic review was performed according to the Minds Handbook for Clinical Practice Guideline Development Ver. 3.0, 2020 [2]. Regarding alcohol consumption in breast cancer patients, the importance of outcomes was examined based on the Minds Handbook. Breast cancer recurrence, breast cancer mortality, and all-cause mortality were judged to be important as harms, and the cardiovascular disease reduction effect was judged to be important as a benefit.

Search strategy and selection criteria

The PubMed, Cochrane Library, and Ichushi-Web databases were searched using the terms “breast neoplasms”, “breast cancer”, “alcohol drinking”, “alcohol consumption”, “prognosis”, “recurrence”, “survival”, and “mortality”. The search was limited to articles published up to March 2021.

According to these criteria, two authors (TN and YK) independently reviewed all titles and abstracts of the retrieved articles. The full articles were evaluated for relevance. Systematic reviews were eligible when they were judged to be of moderate quality according to AMSTAR [3] and included studies fulfilling the inclusion criteria. Authors were allowed to independently search the articles and add them to the list when they met all inclusion criteria (hand-searching). Reviews, articles on breast cancer incidence, very low population numbers, and articles with missing outcome data were excluded.

Quality assessment and data extraction

The qualities of the trials selected through the process described above were evaluated according to the Minds Handbook for Clinical Practice Guideline Development Ver. 3.0, 2020 [2].

Statistical analysis

Review Manager software 5.4 (https://review-manager.software.informer.com/5.4/) was used for statistical analysis. The summary of relative risk (RR) (hazard ratio or risk ratio) and 95% confidence intervals (95% CI) for the highest and lowest categories of alcohol intake were estimated using the inverse variance method.

RR < 1 favored alcohol intake. The heterogeneity of the trials’ results was assessed by inspecting graphical presentations; the Chi-squared test was used to evaluate heterogeneity, and I2 statistics were used to evaluate inconsistency. Significant heterogeneity was defined as I2 statistic > 50%. All analyses were performed using a random effects model. A funnel plot estimating the precision of a trial was examined for asymmetry to estimate publication bias. The outcomes of this meta-analysis were breast cancer recurrence, breast cancer-specific death, all-cause and cardiovascular disease mortality.

Results

Literature search results

The database search identified 725 potentially relevant articles, and hand-searching was used to identify six studies. In the 1st screening, 668 studies were excluded, leaving 63 systematic review articles. In the 2nd screening, 31 papers met the criteria and were judged eligible (Fig. 1). Alcohol consumption and breast cancer recurrence, breast cancer-related morality, all-cause mortality in breast cancer patients and cardiovascular disease mortality in breast cancer patients or healthy participants were assessed.

Fig. 1.

Fig. 1

Open in a new tab

Results of the search

Overview of included studies

Table 1 presents an overview of the characteristics of the included studies of pre- and post-diagnosis alcohol consumption and/or breast cancer recurrence, breast cancer-related mortality, all-cause mortality, and cardiovascular disease mortality. All studies meeting the inclusion criteria were observational, with 32 being cohort studies and 1 a case–control study. Data collection ranged between 1982 and 2013. Effect measures used were the hazard ratio or the risk ratio. The studies included in this systematic review presented data from 4638 cases of recurrence, 12,209 cases of breast cancer-related mortality, 21,945 cases of all-cause mortality, and 7727 cases of cardiovascular disease mortality. The participants were women diagnosed with in situ or invasive breast cancer (TNM Stage 0-IC). Median or mean follow-up was 31.56 months to 11.3 years. Exposure times were pre-diagnosis 24, post-diagnosis 7, and pre- and post-diagnosis 2. Alcohol exposure varied from over 4 g/day to over 30 g/day.

Table 1.

Characteristics of included studies of pre- and post-diagnosis alcohol consumption and/or breast cancer recurrence, mortality (breast cancer, all-cause, cardiovascular disease)

References Study Study design Deta collection period Effect measure Sample size (N) Recurrence Breast deaths All-cause deaths Cardiovascular deaths Follow up (median or mean) Exposure time (pre/post diagnosis) Stage Exposure
[4] Hebert 1998 Cohort 1982–1984 RR 472 109 73 87 – 8–10 y Pre I–IIIa 12 Oz beer
[5] Saxe 1999 Cohort 1989–1991 HR 149 28 26 – – 5 y <  Pre All 2drink/d < 
[6] Muscat2003 Case–control 1994–1996 RR 224 30 – – – 3.6 y Pre All 1drink/d < 
[7] Brewster2007 Cohort 1985–2000 HR 2327 332 – – – 5 y <  Pre I–II heavy
[8] Vrieling2012 Cohort 2001–2005 HR 2522 247 235 316 20 4.4–7.4 y Pre I–IV 12 g < 
[9] Holm2013 Cohort 1993–1997 HR 1052 110 106 – – 6 y Pre I–IIIa 20 g < 
[10] Kowalski2018 Cohort 2007–2012 HR 1399 358 – – – 31.56 m (mean) Pre I–IV 7drink/w < 
[11] Flatt2010 Cohort 1995–2000 HR 3088 518 262 315 – 7.3 y Pre I–IIIa 300 g/m < 
[12] Kwan2013 Cohort 1990–2006 HR 9329 1487 911 1542 156 10.3 y Post I–IIIa 6 g/d < 
[13] Nechuta2016 Cohort 1990–2006 HR 6596 1309 – 1427 – 10.5 y Post I–III 12 g/d < 
[14] Lowry2016 Cohort No info HR 7835 – 622 1625 – 7.9 y Pre/post 0–III 7drink/w < 
[15] Hellmann2010 Cohort 1976–1978, 1981–1983, 1991–1994, 2001–2003 HR 528 – 178 323 – 7.8 y Pre Local-metastases 14unit/w < 
[16] Newcomb2013 Cohort 1988–1995, 1997–2008 HR 22,890 – 3484 7780 1531 11.3 y Pre/post All 10drink/w < 
[17] Din2016 Cohort 1984–1985,1987–1988 HR 939 – 303 – – 11 y Pre All 10-36drink/w < 
[18] Weaver2013 Cohort 1996–2001 HR 1097 – 92 154 – 86 m (mean) Post All 4drink/d < 
[19] Ali(pooled)
SEARCH Cohort 1991–1996 HR 8446 – 765 945 – 6 y Post I–IV 14drink/w < 
EPIC Cohort 1992–2000 HR 10,561 – 174 395 – 7 y Pre I–IV 14drink/w < 
BCAC Cohort No information HR 10,232 – 355 963 – 6 y Pre I–IV 14drink/w < 
[20] Harris2012 Cohort 1987–2008 HR 3146 – 385 860 – 8.2 y Pre I–IV 10 g/d < 
[21] Dal Maso2008 Cohort 1991–1994 HR 1453 – 398 503 – 12.4 y Pre I–IV 2drink/d < 
[22] Borugian2004 Cohort 1991–1992 RR 603 – 112 – – 8 y Pre 0–III 1% increases in energy
[23] Allemani2011 Cohort 1987–1992 RR 264 – 43 – – 7 y Pre I–IV 13 g/d < 
[24] Jain2000 Cohort 1980–1985 HR 58,926 – 223 – – 10.3 y Pre No info 20 g/d < 
[25] Thun1997 Cohort 1982–1991 RR 251,420 – 691 – 5517 9 y Pre All 4drink/d < 
[26] Ma2019 Cohort 1994–1998 HR 4523 – 824 1055 – 8.6 y Pre No info 7drink/w < 
[27] Minami2019 Cohort 1997–2013 HR 1420 – 193 261 – 8.6 y Pre All ever/current
[28] Zeinomar2017 Cohort 1996–2011 HR 1116 – 58 211 – 9.1 y Pre All 3drink/w < 
[29] Beasley2011 Cohort 1998–2001 HR 4441 – 137 525 – 5.5 y Post Local and regional quintile 5(med 15%kcal)
[30] Fuchs1995 Cohort 1980, 1984, 1986 RR 85,709 – 350 2658 503 12 y Post All 30 g/d < 
[31] Breslow2010 Cohort 1988–1991,1997–2004 RR 184,764 – 677 – – 11 y Post All 7drink/w < 
[32] Rohan1993 Cohort 1982–1984 HR 412 – 112 – – 5.5 y Pre No info 10 g/d < 
[33] Reding2008 Cohort 1983–1992 HR 1286 – 364 – – 12 y Pre All 7drink/w < 
[34] Zhang1995 Cohort 1986–1991 RR 698 – 56 – – 2.9 y Pre All 4 g/d < 
Open in a new tab

HR hazard ratio, RR risk ratio

Evaluation of the risk of bias

The Cochrane risk-of-bias assessment was performed to evaluate the quality of the 33 included studies (Table 2). Non-exposed cohort bias was present in all studies because these studies were observational and not randomly assigned. On the other hand, there was a low risk of allocation concealment, blinding of participants and personnel, and selective reporting. Incomplete outcome data were rated as unclear risk of bias in 6 cases with an observation period of less than 5 years and as high risk of bias in 1 case with an observation period of less than 3 years. Regarding the adjustment of confounding factors item, there were 7 studies in which adjustment for confounding factors was hardly performed, and 5 studies in which it was evaluated as inadequate.

Table 2.

Risk of bias summary

graphic file with name 12282_2023_1455_Tab2_HTML.jpg

Open in a new tab

Association between alcohol consumption and breast cancer recurrence

There were 7 pre-diagnosis studies [4–10] and 3 post-diagnosis studies [11–13] of alcohol consumption and breast cancer recurrence in breast cancer patients. The risk of recurrence increased in two pre-diagnosis studies [4, 9] and in one post-diagnosis study limited to postmenopausal cases [12], but the risk was not significant in other studies.

In the meta-analysis of seven studies, the RR for pre-diagnosis alcohol intake was 1.02 (95% CI 0.77–1.37, p = 0.88), showing high heterogeneity in the effect (I2 = 69%), and no significant risk was observed. The RR for the post-diagnosis alcohol intake was 0.96 (95% CI 0.85–1.10, p = 0.57), showing no heterogeneity in the effect (I2 = 0%), and no significant risk was observed (Fig. 2A, B).

Fig. 2.

Fig. 2

Open in a new tab

Forest plots of the hazard ratio for alcohol intake and breast cancer recurrence. A Pre-diagnosis; B post-diagnosis

Association between alcohol consumption and breast cancer-related mortality

There were 21 pre-diagnosis studies [4, 8, 9, 14–28] and 9 post-diagnosis studies [12, 14, 16, 19, 29–32] of alcohol consumption and breast cancer-related mortality in breast cancer patients. For pre-diagnosis alcohol intake, increased risk was observed in four studies [4, 8, 23, 24] and decreased risk in two studies [26, 27], but the risk was not significant in other studies. For post-diagnosis alcohol intake, increased risk was observed in 1 study [30] and 1 study [12] when limited to postmenopausal cases.

In the meta-analysis of 21 studies, the RR for pre-diagnosis alcohol intake was 1.02 (95% CI 0.93–1.11, p = 0.69), showing high heterogeneity in the effect (I2 = 60%), but not significant. In nine studies, the RR for post-diagnosis alcohol intake was 0.96 (95% CI 0.77–1.19, p = 0.70), showing slight heterogeneity in the effect (I2 = 38%), but not significant (Fig. 3A, B).

Fig. 3.

Fig. 3

Open in a new tab

Forest plots of the hazard ratio for alcohol intake and breast cancer-related morality. A Pre-diagnosis; B post-diagnosis; C ER-positive cases; D ER-negative cases

In addition, five studies of estrogen receptor (ER) expression status were reported in relation to breast cancer-related death [14, 19, 27], three studies of pre-diagnosis alcohol intake [14, 19] and two studies of post-diagnosis alcohol intake [19, 27]. In the meta-analysis, the RR for the ER-positive cases was 0.77 (95% CI 0.59–1.00, p = 0.05), showing no heterogeneity in the effect (I2 = 0%), and the risk was slightly reduced (Fig. 3C). The RR for ER-negative cases was 0.79 (95% CI 0.56–1.11, p = 0.17), showing slight heterogeneity (I2 = 39%), but not significant (Fig. 3D).

Association between alcohol consumption and all-cause mortality

There were 18 pre-diagnosis studies [5, 8, 11, 14–16, 18–21, 26–28, 33, 34] and 8 post-diagnosis studies [12, 13, 16, 19, 29, 30] of alcohol consumption and all-cause mortality in breast cancer patients. For pre-diagnosis alcohol intake, decreased risk was observed in three studies [11, 19, 33]. For post-diagnosis alcohol intake, increased risk was observed in one study [30], with decreased risk in three studies [12, 14, 19].

In the meta-analysis of 18 studies, the RR for pre-diagnosis alcohol intake was 0.90 (95% CI 0.82–0.98, p = 0.02), showing slight heterogeneity in the effect (I2 = 37%), and the risk was significantly reduced (Fig. 4A). The meta-analysis of seven studies showed that the RR for post-diagnosis alcohol intake was 0.88 (95% CI 0.77–1.02, p = 0.08), showing high heterogeneity in the effect (I2 = 67%), and the risk was not significantly reduced (Fig. 4B).

Fig. 4.

Fig. 4

Open in a new tab

Forest plots of the hazard ratio for alcohol intake and all-cause mortality. A Pre-diagnosis; B post-diagnosis; C ER-positive cases; D ER-negative cases

In addition, five studies of ER expression status in relation to all-cause death were reported. Risk reduction was observed in one ER-positive study [19] and three ER-negative studies [14, 19, 27], with three studies of pre-diagnosis alcohol intake [14, 19] and two studies of post-diagnosis alcohol intake [19, 27]. In the meta-analysis, the RR for ER-positive cases was 0.79 (95% CI 0.68–0.92, p = 0.003), showing no heterogeneity in the effect (I2 = 4%), and the risk was significantly reduced (Fig. 4c).

The RR for ER-negative cases was 0.68 (95% CI 0.50–0.91, p = 0.01), showing slight heterogeneity (I2 = 32%), and the risk was significantly reduced (Fig. 4d).

Association between alcohol consumption and cardiovascular disease mortality

There were two post-diagnosis studies [12, 16] of alcohol consumption and cardiovascular disease mortality in breast cancer patients. For post-diagnosis alcohol intake, decreased risk was observed in one study [16]. In two studies [12, 16], the RR for breast cancer patients was 0.47 (95% CI 0.28–0.79, p = 0.005), showing no heterogeneity in the effect (I2 = 0%), and the risk was significantly reduced (Fig. 5).

Fig. 5.

Fig. 5

Open in a new tab

Forest plots of the hazard ratio for alcohol intake and cardiovascular disease mortality

Discussion

Alcohol consumption has been reported to increase breast cancer incidence in healthy individuals [35]. However, it is unclear whether alcohol consumption affects breast cancer recurrence, breast cancer-related death, or all-cause death in breast cancer patients. Therefore, a systematic review and meta-analysis of epidemiological studies in breast cancer patients was performed. There were no significant associations between alcohol consumption and breast cancer recurrence [4–13] and breast cancer-related mortality [4, 8, 9, 12, 14–32]. There was high heterogeneity between pre-diagnosis alcohol consumption and breast cancer recurrence and breast cancer-related mortality. This may be due to the insufficient follow-up period in several cases [6, 8, 10, 18, 34] and the variability in the number of events (breast cancer recurrence: 28–1487 cases; breast cancer-related mortality: 26–824 cases) as shown in Table 1. On the other hand, a significant inverse association between pre-diagnosis alcohol consumption and all-cause morality [5, 8, 10, 14–16, 18–21, 26–28, 33, 34] and a significant inverse association between post-diagnosis alcohol consumption and cardiovascular disease mortality were found [12, 16].

Low to moderate amounts of weekly or daily alcohol consumption may be beneficial to cardiovascular health [36, 37]. The reduction in all-cause mortality associated with alcohol consumption after the diagnosis of breast cancer was thought to be related to decreased cardiovascular disease mortality. However, the relationship between alcohol consumption and cardiovascular disease mortality in patients with cardiovascular disease appears to be biphasic and have a J-shaped association [38].

Population level recommendations for upper limits of alcohol consumption exist in many nations as part of public health strategies aimed at reducing adverse health effects. These recommendations vary from country to country. For example, the United States Department of Agriculture recommends women consume not more than 1 standard drink per day (where 1 drink = 14 g of alcohol) [39].

The Ministry of Health, Labour and Welfare of Japan recommends consuming not more than 20 g of alcohol per day. However, this evidence is based on Tsugane’s study [40] and is the result for men. For women, smaller amounts than for men are considered appropriate, because women are smaller than men and are thought to break down alcohol more slowly. Indeed, an increased relative risk of all-cause mortality from alcohol drinking for men is found at 6 or more drinks, whereas for women it is found at 2.0–2.9 drinks [41].

Regarding ER status, we examined it in 5 studies [14, 19, 27]. Regarding the association between alcohol consumption and breast cancer-related death, the HR for ER-positive cases was 0.77 (95% CI 0.59–1.00, p = 0.05), and the HR for ER-negative cases was 0.79 (95% CI 0.56–1.11, p = 0.17). Regarding the association between alcohol consumption and all-cause death, the HR for ER-positive cases was 0.79 (95% CI 0.68–0.92, p = 0.002), the HR for ER-negative cases was 0.68 (95% CI 0.50–0.91, p = 0.01), and the risk was significantly reduced. There was no clear significant difference in risk associated with ER status.

There are several limitations of this systematic review. First, study selection involved filtering for English and Japanese language articles, potentially resulting in the exclusion of relevant, non-English publications. Second, in some studies, analyses were either performed without adjusting for any confounding factors, or analyses did not account for the factors considered most important in regard to the outcome of interest, such as age, BMI, and stage of the initial breast cancer.

Third, since alcohol consumption status is mainly based on questionnaire surveys, the exact amount and frequency of alcohol consumption are not known. In addition, there is the possibility of underreporting.

The present findings led us to create the recommendation for the clinical question in the Japanese Breast Cancer Society Clinical Practice Guideline Committee, 2022 edition, as follows: Whether pre-diagnosis or post-diagnosis, alcohol consumption has a substantial effect on risk and is unlikely to increase the risk of breast cancer recurrence and death from breast cancer.

However, excessive alcohol consumption increases the relative risk of all-cause mortality, and alcohol consumption should be limited to a moderate level as defined by each country.

Declarations

Conflict of interest

The authors declare no conflict of interest.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 100E: Personal habits and indoor combustions. IARC Lyon 2012. [PMC free article] [PubMed]
  • 2.Minds Manual Developing Committee ed. Minds Manual for Guideline Development 2020 ver.3.0. Tokyo: Japan Council for Quality Health Care, 2021.
  • 3.Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol. 2009;62:1013–1020. doi: 10.1016/j.jclinepi.2008.10.009. [DOI] [PubMed] [Google Scholar]
  • 4.Hebert JR, Hurley TG, Ma Y. The effect of dietary exposures on recurrence and mortality in early stage breast cancer. Breast Cancer Res Treat. 1998;51(1):17–28. doi: 10.1023/A:1006056915001. [DOI] [PubMed] [Google Scholar]
  • 5.Saxe GA, Rock CL, Wicha MS, Schottenfeld D. Diet and risk for breast cancer recurrence and survival. Breast Cancer Res Treat. 1999;53(3):241–253. doi: 10.1023/A:1006190820231. [DOI] [PubMed] [Google Scholar]
  • 6.Muscat JE, Britton JA, Djordjevic MV, Citron ML, Kemeny M, Busch-Devereaux E, et al. Adipose concentrations of organochlorine compounds and breast cancer recurrence in Long Island New York. Cancer Epidemiol Biomark Prev. 2003;12(12):1474–1478. [PubMed] [Google Scholar]
  • 7.Brewster AM, Do KA, Thompson PA, Hahn KM, Sahin AA, Cao Y, et al. Relationship between epidemiologic risk factors and breast cancer recurrence. J Clin Oncol. 2007;25(28):4438–4444. doi: 10.1200/JCO.2007.10.6815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Vrieling A, Buck K, Heinz J, Obi N, Benner A, Flesch-Janys D, et al. Pre-diagnostic alcohol consumption and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Res Treat. 2012;136(1):195–207. doi: 10.1007/s10549-012-2230-2. [DOI] [PubMed] [Google Scholar]
  • 9.Holm M, Olsen A, Christensen J, Kroman NT, Bidstrup PE, Johansen C, et al. Pre-diagnostic alcohol consumption and breast cancer recurrence and mortality: results from a prospective cohort with a wide range of variation in alcohol intake. Int J Cancer. 2013;132(3):686–694. doi: 10.1002/ijc.27652. [DOI] [PubMed] [Google Scholar]
  • 10.Kowalski A, Striley CW, Varma DS, Egan KM, Yaghjyan L. Interactions between alcohol consumption and adjuvant hormone therapy in relation to breast cancer-free survival. J Breast Cancer. 2018;21(2):158–164. doi: 10.4048/jbc.2018.21.2.158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Flatt SW, Thomson CA, Gold EB, Natarajan L, Rock CL, Al-Delaimy WK, et al. Low to moderate alcohol intake is not associated with increased mortality after breast cancer. Cancer Epidemiol Biomark Prev. 2010;19(3):681–688. doi: 10.1158/1055-9965.EPI-09-0927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Kwan ML, Chen WY, Flatt SW, Weltzien EK, Nechuta SJ, Poole EM, et al. Postdiagnosis alcohol consumption and breast cancer prognosis in the after breast cancer pooling project. Cancer Epidemiol Biomark Prev. 2013;22(1):32–41. doi: 10.1158/1055-9965.EPI-12-1022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Nechuta S, Chen WY, Cai H, Poole EM, Kwan ML, Flatt SW, et al. A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis. Int J Cancer. 2016;138(9):2088–2097. doi: 10.1002/ijc.29940. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lowry SJ, Kapphahn K, Chlebowski R, Li CI. Alcohol use and breast cancer survival among participants in the women's health initiative. Cancer Epidemiol Biomark Prev. 2016;25(8):1268–1273. doi: 10.1158/1055-9965.EPI-16-0151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Hellmann SS, Thygesen LC, Tolstrup JS, Grønbaek M. Modifiable risk factors and survival in women diagnosed with primary breast cancer: results from a prospective cohort study. Eur J Cancer Prev. 2010;19(5):366–373. doi: 10.1097/CEJ.0b013e32833b4828. [DOI] [PubMed] [Google Scholar]
  • 16.Newcomb PA, Kampman E, Trentham-Dietz A, Egan KM, Titus LJ, Baron JA, et al. Alcohol consumption before and after breast cancer diagnosis: associations with survival from breast cancer, cardiovascular disease, and other causes. J Clin Oncol. 2013;31(16):1939–1946. doi: 10.1200/JCO.2012.46.5765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Din N, Allen IE, Satariano WA, Demb J, Braithwaite D. Alcohol consumption and mortality after breast cancer diagnosis: the health and functioning in women study. Breast Dis. 2016;36(2–3):77–89. doi: 10.3233/BD-150202. [DOI] [PubMed] [Google Scholar]
  • 18.Weaver AM, McCann SE, Nie J, Edge SB, Nochajski TH, Russell M, et al. Alcohol intake over the life course and breast cancer survival in Western New York exposures and breast cancer (WEB) study: quantity and intensity of intake. Breast Cancer Res Treat. 2013;139(1):245–253. doi: 10.1007/s10549-013-2533-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Ali AM, Schmidt MK, Bolla MK, Wang Q, Gago-Dominguez M, Castelao JE, et al. Alcohol consumption and survival after a breast cancer diagnosis: a literature-based meta-analysis and collaborative analysis of data for 29,239 cases. Cancer Epidemiol Biomark Prev. 2014;23(6):934–945. doi: 10.1158/1055-9965.EPI-13-0901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Harris HR, Bergkvist L, Wolk A. Alcohol intake and mortality among women with invasive breast cancer. Br J Cancer. 2012;106(3):592–595. doi: 10.1038/bjc.2011.561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Dal Maso L, Zucchetto A, Talamini R, Serraino D, Stocco CF, Vercelli M, et al. Prospective Analysis of Case-control studies on Environmental factors and health (PACE) study group. Effect of obesity and other lifestyle factors on mortality in women with breast cancer. Int J Cancer. 2008;123(9):2188–2194. doi: 10.1002/ijc.23747. [DOI] [PubMed] [Google Scholar]
  • 22.Borugian MJ, Sheps SB, Kim-Sing C, Van Patten C, Potter JD, Dunn B, et al. Insulin, macronutrient intake, and physical activity: are potential indicators of insulin resistance associated with mortality from breast cancer? Cancer Epidemiol Biomark Prev. 2004;13(7):1163–1172. doi: 10.1158/1055-9965.1163.13.7. [DOI] [PubMed] [Google Scholar]
  • 23.Allemani C, Berrino F, Krogh V, Sieri S, Pupa SM, Tagliabue E, et al. Do pre-diagnostic drinking habits influence breast cancer survival? Tumori. 2011;97(2):142–148. doi: 10.1177/030089161109700202. [DOI] [PubMed] [Google Scholar]
  • 24.Jain MG, Ferrenc RG, Rehm JT, Bondy SJ, Rohan TE, Ashley MJ, et al. Alcohol and breast cancer mortality in a cohort study. Breast Cancer Res Treat. 2000;64(2):201–209. doi: 10.1023/A:1006402323445. [DOI] [PubMed] [Google Scholar]
  • 25.Thun MJ, Peto R, Lopez AD, Monaco JH, Henley SJ, Heath CW, Jr, et al. Alcohol consumption and mortality among middle-aged and elderly US adults. N Engl J Med. 1997;337(24):1705–1714. doi: 10.1056/NEJM199712113372401. [DOI] [PubMed] [Google Scholar]
  • 26.Ma H, Malone KE, McDonald JA, Marchbanks PA, Ursin G, Strom BL, et al. Pre-diagnosis alcohol consumption and mortality risk among black women and white women with invasive breast cancer. BMC Cancer. 2019;19(1):800. doi: 10.1186/s12885-019-5991-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Minami Y, Kanemura S, Kawai M, Nishino Y, Tada H, Miyashita M, et al. Alcohol consumption and survival after breast cancer diagnosis in Japanese women: a prospective patient cohort study. PLoS ONE. 2019;14(11):e0224797. doi: 10.1371/journal.pone.0224797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Zeinomar N, Thai A, Cloud AJ, McDonald JA, Liao Y, Terry MB. Alcohol consumption and breast cancer-specific and all-cause mortality in women diagnosed with breast cancer at the New York site of the Breast Cancer Family Registry. PLoS ONE. 2017;12(12):e0189118. doi: 10.1371/journal.pone.0189118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Beasley JM, Newcomb PA, Trentham-Dietz A, Hampton JM, Bersch AJ, Passarelli MN, et al. Post-diagnosis dietary factors and survival after invasive breast cancer. Breast Cancer Res Treat. 2011;128(1):229–236. doi: 10.1007/s10549-010-1323-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Fuchs CS, Stampfer MJ, Colditz GA, Giovannucci EL, Manson JE, Kawachi I, et al. Alcohol consumption and mortality among women. N Engl J Med. 1995;332(19):1245–1250. doi: 10.1056/NEJM199505113321901. [DOI] [PubMed] [Google Scholar]
  • 31.Breslow RA, Chen CM, Graubard BI, Mukamal KJ. Prospective study of alcohol consumption quantity and frequency and cancer-specific mortality in the US population. Am J Epidemiol. 2011;174(9):1044–1053. doi: 10.1093/aje/kwr210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Rohan TE, Hiller JE, McMichael AJ. Dietary factors and survival from breast cancer. Nutr Cancer. 1993;20(2):167–177. doi: 10.1080/01635589309514283. [DOI] [PubMed] [Google Scholar]
  • 33.Reding KW, Daling JR, Doody DR, O'Brien CA, Porter PL, Malone KE. Effect of prediagnostic alcohol consumption on survival after breast cancer in young women. Cancer Epidemiol Biomark Prev. 2008;17(8):1988–1996. doi: 10.1158/1055-9965.EPI-07-2897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Zhang S, Folsom AR, Sellers TA, Kushi LH, Potter JD. Better breast cancer survival for postmenopausal women who are less overweight and eat less fat. The Iowa Women's Health Study. Cancer. 1995;76(2):275–283. doi: 10.1002/1097-0142(19950715)76:2&#x0003c;275::AID-CNCR2820760218&#x0003e;3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  • 35.Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2015;112(3):580–593. doi: 10.1038/bjc.2014.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Bell S, Daskalopoulou M, Rapsomaniki E, George J, Britton A, Bobak M, et al. Association between clinically recorded alcohol consumption and initial presentation of 12 cardiovascular diseases: population based cohort study using linked health records. BMJ. 2017;356:j909. doi: 10.1136/bmj.j909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Bergmann MM, Rehm J, Klipstein-Grobusch K, Boeing H, Schütze M, Drogan D, et al. The association of pattern of lifetime alcohol use and cause of death in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Int J Epidemiol. 2013;42(6):1772–1790. doi: 10.1093/ije/dyt154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Ding C, O'Neill D, Bell S, Stamatakis E, Britton A. Association of alcohol consumption with morbidity and mortality in patients with cardiovascular disease: original data and meta-analysis of 48,423 men and women. BMC Med. 2021;19(1):167. doi: 10.1186/s12916-021-02040-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2020–2025 Dietary Guidelines for Americans. http://www.dietaryguidelines.gov/sites/default/files/2021-03/Dietary Guidelines for Americans, 2020–2025
  • 40.Tsugane S, Fahey MT, Sasaki S, Baba S. Alcohol consumption and all-cause and cancer mortality among middle-aged Japanese men: seven-year follow-up of the JPHC study Cohort I. Japan Public Health Center. Am J Epidemiol. 1999;150(11):1201–1207. doi: 10.1093/oxfordjournals.aje.a009946. [DOI] [PubMed] [Google Scholar]
  • 41.Holman CD, English DR, Milne E, Winter MG. Meta-analysis of alcohol and all-cause mortality: a validation of NHMRC recommendations. Med J Aust. 1996;164(3):141–145. doi: 10.5694/j.1326-5377.1996.tb122011.x. [DOI] [PubMed] [Google Scholar]

Articles from Breast Cancer (Tokyo, Japan) are provided here courtesy of Springer

RESOURCES